O
AXDX

OppenheimerFunds’s Accelerate Diagnostics AXDX Stock Holding History

OppenheimerFunds’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-26,521
Closed -$5.95M – 1839
2017
Q3 		$5.95M Buy
26,521
+3,207
+14% +$788K 0.01% 796
2017
Q2 		$6.38M Buy
+23,314
New +$6.32M 0.01% 798

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

OppenheimerFunds's AXDX Position: Q4 2017 in Review

OppenheimerFunds sold out of Accelerate Diagnostics (AXDX) in Q4 2017, closing a stake of 26,521 shares — an estimated $5.95M sold.

OppenheimerFunds first reported a position in AXDX in Q2 2017 and held it in 2 quarters. The position peaked at $6.38M in Q2 2017. 118 funds tracked by Wall St. Rank hold AXDX as of Q4 2017.

  • OppenheimerFunds reported no remaining Accelerate Diagnostics position as of Q4 2017 after selling out during the quarter.
  • OppenheimerFunds sold 26,521 Accelerate Diagnostics shares in Q4 2017, an estimated $5.95M.
  • OppenheimerFunds first reported a position in Accelerate Diagnostics in Q2 2017 and held it in 2 quarters.
  • OppenheimerFunds's Accelerate Diagnostics position peaked at $6.38M in Q2 2017.
  • 118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2017.

Based on OppenheimerFunds's 13F filing for Q4 2017, filed 12 Feb 2018.